Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
12.99 USD | +1.41% | -2.55% | -39.72% |
Apr. 29 | Truist Securities Cuts Teladoc's Price Target to $15 From $17, Maintains Hold Rating | MT |
Apr. 26 | UBS Adjusts Teladoc Price Target to $16 From $20, Maintains Neutral Rating | MT |
Financials (USD)
Sales 2024 * | 2.66B | Sales 2025 * | 2.76B | Capitalization | 2.17B |
---|---|---|---|---|---|
Net income 2024 * | -177M | Net income 2025 * | -111M | EV / Sales 2024 * | 0.93 x |
Net Debt 2024 * | 295M | Net Debt 2025 * | 44.72M | EV / Sales 2025 * | 0.8 x |
P/E ratio 2024 * |
-11.9
x | P/E ratio 2025 * |
-18.9
x | Employees | 5,208 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 0% |
Latest transcript on Teladoc Health, Inc.
1 day | +1.41% | ||
1 week | -5.39% | ||
Current month | +1.88% | ||
1 month | -12.53% | ||
3 months | -34.53% | ||
6 months | -21.98% | ||
Current year | -39.72% |
Managers | Title | Age | Since |
---|---|---|---|
Mala Murthy
CEO | Chief Executive Officer | 60 | 19-06-23 |
Jeff Nadler
CTO | Chief Tech/Sci/R&D Officer | - | 11-01-31 |
Nikolaos Nanis
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
David Snow
CHM | Chairman | 69 | 14-01-31 |
Sandra Fenwick
BRD | Director/Board Member | 73 | 20-11-18 |
David Shedlarz
BRD | Director/Board Member | 75 | 16-09-18 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
4.31% | 1 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-02 | 12.99 | +1.41% | 5,025,164 |
24-05-01 | 12.81 | +0.47% | 4,405,650 |
24-04-30 | 12.75 | -4.78% | 6,303,861 |
24-04-29 | 13.39 | +2.92% | 6,522,236 |
24-04-26 | 13.01 | -2.40% | 7,696,741 |
Delayed Quote Nyse, May 02, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-39.72% | 2.17B | |
+23.23% | 536M | |
+42.77% | 467M | |
-65.08% | 157M | |
-37.84% | 74.88M |
- Stock Market
- Equities
- TDOC Stock